PCRX - Pacira Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Pacira Pharmaceuticals, Inc.

5 Sylvan Way
Suite 300
Parsippany, NJ 07054
United States
973-254-3560
http://www.pacira.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees503

Key Executives

NameTitlePayExercisedAge
Mr. David M. StackChairman and Chief Exec. Officer1.17M4.52M67
Mr. Charles A. Reinhart IIIChief Financial Officer386.83kN/A56
Dr. Scott BraunsteinSr. VP of Strategy & Corp. Devel.554.4kN/A54
Ms. Kristen Williams J.D.Chief Admin. Officer, Gen. Counsel and Sec.552.13kN/A43
Ms. Lauren Bullaro RikerPrincipal Accounting Officer & VP of Fin.N/AN/A38
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. Its development pipeline comprises DepoTranexamic Acid, a long-acting local antifibrinolytic agent, which is in Phase II clinical development for the treatment or prevention of excessive blood loss during surgery by preventing the breakdown of a clot; and DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical development for the treatment of acute postsurgical pain. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. is headquartered in Parsippany, New Jersey.

Corporate Governance

Pacira Pharmaceuticals, Inc.’s ISS Governance QualityScore as of February 1, 2018 is 8. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.